Biology of Blood and Marrow Transplantation
Volume 13, Issue 12 , Pages 1487-1498 , December 2007

Higher Risk of Cytomegalovirus and Aspergillus Infections in Recipients of T Cell–Depleted Unrelated Bone Marrow: Analysis of Infectious Complications in Patients Treated with T Cell Depletion Versus Immunosuppressive Therapy to Prevent Graft-versus-Host Disease

  • Jo-Anne H. van Burik

      Affiliations

    • Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis, Minnesota
    • Corresponding Author InformationCorrespondence and reprint requests: Jo-Anne van Burik, MMC 250, 420 Delaware Street SE, Minneapolis, MN, 55455; Tel: 612- 625-8462; Fax: 612-625-4410.
    • ,
  • Shelly L. Carter

      Affiliations

    • The EMMES Corporation, Rockville, Maryland
    • ,
  • Alison G. Freifeld

      Affiliations

    • Department of Medicine, University of Nebraska, Omaha, Nebraska
    • ,
  • Kevin P. High

      Affiliations

    • Department of Medicine, Wake Forest University, Winston-Salem, North Carolina
    • ,
  • Kamar T. Godder

      Affiliations

    • Department of Pediatrics, Virginia Commonwealth University, Richmond, Virginia
    • ,
  • Genovefa A. Papanicolaou

      Affiliations

    • Departments of Medicine and Pediatrics, Memorial-Sloan Kettering Cancer Center, New York, New York
    • ,
  • Adam M. Mendizabal

      Affiliations

    • The EMMES Corporation, Rockville, Maryland
    • ,
  • John E. Wagner

      Affiliations

    • Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis, Minnesota
    • ,
  • Saul Yanovich

      Affiliations

    • Department of Medicine, Medical College of Virginia, Richmond, Virginia
    • ,
  • Nancy A. Kernan

      Affiliations

    • Departments of Medicine and Pediatrics, Memorial-Sloan Kettering Cancer Center, New York, New York

Received 17 July 2007 ,Accepted 30 August 2007.

References 

  1. Ringden O, Deeg HJ. Clinical spectrum of graft-versus-host disease. In:  Ferrara J,  Deeg H,  Burakoff S editor. Graft-vs-Host Disease. 2nd ed. New York: Marcel Dekker; 1996;p. 525–560
  2. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593–602
  3. Wagner JE, Thompson JS, Carter SL, et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-Cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005;366:733–741
  4. Wagner JE, Santos GW, Noga SJ, et al. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. Blood. 1990;75:1370–1377
  5. Kawanishi Y, Passweg J, Drobyski WR, et al. Effect of T-cell subset dose on outcome of T-cell–depleted bone marrow transplantation. Bone Marrow Transplant. 1997;19:1069–1077
  6. Dykewicz CA. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. Biol Blood Marrow Transplant. 2001;7:19S–22S
  7. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706
  8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  9. Sposto R, Stablein D, Carter-Campbell S. A partially grouped log-rank test. Stat Med. 1997;16:695–704
  10. Cox DR. Regression models and life tables. J Royal Stat Soc Bull. 1972;34:187–220
  11. Weisdorf DJ, Hurd D, Carter S, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant. 2003;9:512–518
  12. Nichols WG. Combating infections in hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2003;1:57–73
  13. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9:543–558
  14. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407–414
  15. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358–4366
  16. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995;86:3979–3986
  17. Frere P, Hermanne JP, Debouge MH, et al. Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures. Bone Marrow Transplant. 2004;33:745–749
  18. Marena C, Zecca M, Carenini ML, et al. Incidence of, and risk factors for, nosocomial infections among hematopoietic stem cell transplantation recipients, with impact on procedure-related mortality. Infect Control Hosp Epidemiol. 2001;22:510–517
  19. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood. 2004;103:2003–2008
  20. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Eng J Med. 1992;326:845–851
  21. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545–1552
  22. van Burik JA, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis: an autopsy study of 355 patients. Medicine (Baltimore). 1998;77:246–254
  23. Wald A, Leisenring W, van Burik JA, et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459–1466
  24. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357–4363
  25. Keating M, Coutre S, Rai K, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma. 2004;4:220–227

PII: S1083-8791(07)00440-5

doi: 10.1016/j.bbmt.2007.08.049

Biology of Blood and Marrow Transplantation
Volume 13, Issue 12 , Pages 1487-1498 , December 2007

Article Tools

* Image Usage & Resolution